Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Enoxaparin + vitamin K antagonist refers to the combination therapy of enoxaparin, a low molecular weight heparin (LMWH), with a vitamin K antagonist (VKA) such as warfarin or acenocoumarol. This regimen is commonly used for the treatment and prevention of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Enoxaparin acts by activating antithrombin III, which inhibits coagulation factor Xa and to a lesser extent coagulation factor IIa, thereby preventing clot formation. Vitamin K antagonists inhibit the enzyme vitamin K epoxide reductase, reducing the synthesis of active clotting factors II, VII, IX, and X in the liver. The combination is often used during initial anticoagulation therapy for VTE; enoxaparin provides immediate anticoagulation while VKAs require several days to achieve therapeutic effect[1][2][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Enoxaparin + vitamin K antagonist.